Journal of Experimental Pharmacology (Jan 2021)
Montelukast: The New Therapeutic Option for the Treatment of Epilepsy
Abstract
Bekalu Amare Tesfaye, Haftom Gebregergs Hailu, Kaleab Alemayehu Zewdie, Muluken Altaye Ayza, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Haftom Gebregergs Hailu Tel +251912085606Fax +251344416681Email [email protected]: Currently, there is no definitive cure for epilepsy. The available medications relieve symptoms and reduce seizure attacks. The major challenge with the available antiepileptic medication is safety and affordability. The repurposing of montelukast for epilepsy can be an alternative medication with a better safety profile. Montelukast is a leukotriene receptor antagonist that binds to the cysteinyl leukotrienes (CysLT) receptors used in the treatment of bronchial asthma and seasonal allergies. Emerging evidence suggests that montelukast’s anti-inflammatory effect can help to maintain BBB integrity. The drug has also neuroprotective and anti-oxidative activities to reduce seizure incidence and epilepsy. The present review summarizes the neuropharmacological actions of montelukast in epilepsy with an emphasis on the recent findings associated with CysLT and cell-specific effects.Keywords: repurposing, seizure, inflammation, cysteinyl leukotriene receptors
